clinical trial · NCT05277051
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline·phase1·active not recruiting·n = 152
NeoplasmsRemzistotugDostarlimabBelrestotugNelistotugGSK5764227
brief summary
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
started
Mar 22, 2022
primary completion
Aug 31, 2027
completion
Aug 31, 2027
last updated
Mar 23, 2026
official title
A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol